Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $227.64 USD
Change Today +0.48 / 0.21%
Volume 1.6M
RCPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

receptos inc (RCPT) Snapshot

Open
$227.50
Previous Close
$227.16
Day High
$228.06
Day Low
$227.21
52 Week High
07/15/15 - $230.87
52 Week Low
07/31/14 - $40.00
Market Cap
7.2B
Average Volume 10 Days
1.5M
EPS TTM
$-4.84
Shares Outstanding
31.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RECEPTOS INC (RCPT)

receptos inc (RCPT) Related Businessweek News

No Related Businessweek News Found

receptos inc (RCPT) Details

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 03/2/15
Founded in 2008

receptos inc (RCPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $534.4K
Co-Founder and Chief Technology Officer
Total Annual Compensation: $317.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $317.0K
Chief Financial Officer
Total Annual Compensation: $386.8K
Chief Medical officer
Total Annual Compensation: $437.8K
Compensation as of Fiscal Year 2014.

receptos inc (RCPT) Key Developments

Receptos, Inc. Announces Results of the Phase 2 Touchstone Trial - Report

Receptos, Inc. reported positive results for the maintenance period of TOUCHSTONE, the Phase 2 trial of ozanimod (formerly RPC1063) in ulcerative colitis (UC). The results showed that the study has met all efficacy endpoints with statistical significance in patients on the 1 mg dose of ozanimod after 32 weeks of treatment. Assessment Of Ozanimod Versus Placebo In Details- The aforesaid study evaluated the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1 mg) of ozanimod versus placebo. This randomized, double-blind, placebo-controlled trial was conducted in 199 patients with moderately-to-severely active UC across 57 sites in 13 countries. Receptos informed that the trial met its primary efficacy and all secondary endpoints for patients with 1 mg dose after 8 weeks of treatment in the induction period. The 103 patients, who achieved clinical response in the maintenance period at the eight week, continued with treatment for 24 more weeks. At week 32, all secondary end-points were positive and statistically significant for the 1 mg dose. The secondary endpoints at week 32 included clinical response, change in the industry standard Mayo score and mucosal improvement on endoscopy. Further, the proportion of patients in clinical remission at week 32 was statistically significant in favor of both the 1 mg group and the 0.5 mg group (p < 0.05) compared to placebo. Plans to start Phase 3Trial - In 2015, the Company plans to go ahead with a Phase 3 program to confirm the findings of Phase 2. The phase 3 trial would be conducted in patients with moderately-to-severely active UC. Furthermore, these results continue to suggest the potential for ozanimod to be used in the treatment of a related inflammatory bowel disease called Crohn's. The Company stated that it would be initiating a Phase 2 study of ozanimod for the treatment of Crohn's disease in 2015.

Celgene Corporation, Receptos, Inc. - M&A Call

To discuss the strategic acquisition of Receptos

Receptos, Inc.(NasdaqGS:RCPT) added to Russell 1000 Index

Receptos, Inc. has been added to Russell 1000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCPT:US $227.64 USD +0.48

RCPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCPT.
View Industry Companies
 

Industry Analysis

RCPT

Industry Average

Valuation RCPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,564.5x
Price/Book 11.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,433.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECEPTOS INC, please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.